Company ProfilePremium

Sigma Healthcare Limited

Company Profile Analysis

Ticker: SIG.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sigma Healthcare Limited - Company showcase

Sigma Healthcare Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sigma Healthcare Limited Overview

Sigma Healthcare is Australia's largest vertically integrated pharmacy group. It combines the country's dominant discount pharmacy franchise, Chemist Warehouse, with a full-line national pharmaceutical wholesale and distribution platform. The February 2025 reverse merger turned a low-margin wholesaler into a franchisor-wholesaler earning a normalised EBIT margin of about 10%. FY26 revenue was A$10.8bn and normalised EBIT was A$1.09bn.

The Chemist Warehouse branded network generated A$10.2bn of Australian store sales across 561 stores in FY26. International store sales across New Zealand, Ireland, the UAE and (from late 2026) the United Kingdom reached a further A$1.6bn. The group also franchises the Amcal and Discount Drug Stores banners and supplies independent pharmacies.

Its moat rests on three things: purchasing scale, a low-cost warehouse supply chain moving more than 579 million units a year, and an owned and exclusive label portfolio approaching A$1bn. Founder control remains high, at roughly 48% of shares held by the Verrocchi and Gance families.


Company's own description

In its FY26 results materials, Sigma describes itself as an integrated healthcare business. Value creation is framed around four pillars:

  1. Domestic — Chemist Warehouse branded network sales.

  2. International — store sales outside Australia.

  3. Product Differentiation — owned and exclusive label sales.

  4. Operating Leverage — delivering benefits from scale.

CEO Vikesh Ramsunder said FY26 shows Sigma is "not simply larger" after the merger but "structurally stronger" (FY26 ASX release, 27 August 2026).

Sigma's market profile describes a group that franchises retail pharmacies in Australia and internationally. As a full-line wholesaler and distributor, it supplies prescription medicines, including Pharmaceutical Benefits Scheme (PBS) medicines, over-the-counter (OTC) products and front-of-store products to more than 3,500 pharmacy customers. Those customers include its own retail network and independent pharmacies (ASX company description via HotCopper).

Independent characterisation

Sigma operates a three-layer model.

Layer 1 — Franchisor and brand owner. Australian law restricts pharmacy ownership to registered pharmacists. Sigma therefore does not own most Australian stores. It franchises them and earns revenue from three sources:

  • wholesale sale of goods to franchisees, which is the dominant line;

  • franchise and marketing fees;

  • margin on owned and exclusive label products.

This is why statutory revenue (A$10.8bn) is close to Australian network sales (A$10.2bn). The key distinction is that Sigma books the wholesale value of goods sold to stores, not consumer retail sales.

Layer 2 — National wholesaler and distributor. Legacy Sigma runs 11 Australian distribution centres with more than 240,000 square metres of capacity. It completes more than 600,000 deliveries a year and distributed more than 579 million units in FY26, up 6.5%. It serves the Chemist Warehouse network, the Amcal and Discount Drug Stores networks, and independent pharmacies. It also provides third-party logistics (3PL) and receives Community Service Obligation (CSO) funding for PBS distribution. The FY26 results presentation records Sigma ranked No.1 wholesaler in an Advantage Group supplier survey.

Layer 3 — International retail. Chemist Warehouse stores operate in New Zealand (about 70 network stores at 1H26), Ireland (17), the UAE (2 stores plus online since October 2025), and the UK (Greenlight JV, first stores expected by December 2026). Bricks-and-mortar stores in China are being progressively closed (announced August 2025). International stores are typically owned or majority-owned rather than franchised. This explains the International segment's much higher gross margin (30.6% in FY26).

Revenue model mix

Revenue typeDescriptionEstimated weightBasis
Product sales (wholesale to franchisees and independents)PBS and non-PBS prescriptions, OTC, vitamins, beauty and front-of-store, sold at wholesaleDominant (>90% of revenue)Derived from segment structure. Exact split not publicly disclosed.
Product sales (owned international stores)Retail sales at company-controlled stores in NZ, Ireland, UAE and UKc. 3.9% (International segment revenue A$421.4m / A$10.8bn, FY26)FY26 release
Franchise and marketing feesFees from franchisees for brand, systems and marketing——
Services / 3PL / CSOLogistics services and government CSO funding——
Subscription / licensingBrand and IP licensing (for example, the UK Greenlight JV licence)Immaterial at present4 May 2026 release

Value chain position

Sigma sits between pharmaceutical and consumer-health manufacturers (originator and generic pharma, vitamin, beauty and fragrance suppliers) and community pharmacies and end consumers. It controls procurement, warehousing, distribution, franchise retail branding and some product development through its owned and exclusive labels. Supplier support (rebates and promotional funding) is a material gross margin driver. The 1H26 and FY26 presentations both cite "mix and supplier support" as margin contributors.

Customer types and end-markets

Consumers: via Chemist Warehouse, My Chemist, Amcal, Discount Drug Stores and online channels. Categories include dispensary (PBS and private scripts, notably GLP-1 weight-loss medicines), vitamins and supplements, cosmetics, fragrance, personal care and baby.

Franchisee pharmacists: 881 franchise stores across Australia at FY25.

Independent pharmacies: as wholesale and 3PL customers.

Government: as funder of the PBS and CSO.

Suppliers: buying promotional, retail media and data services. This is an emerging area; no specific disclosure was found.

Strategy

Stated strategy

Sigma's FY26 materials organise strategy around four value-creation pillars:

  1. Domestic: grow the Australian CW-branded network (24 stores in FY26; 13 planned for 1H27) and LFL sales.

  2. International: expand CW in New Zealand, Ireland, the UAE and the UK; exit China.

  3. Product Differentiation: owned and exclusive label (c. A$1.0bn; 470+ new lines in FY26).

  4. Operating Leverage: scale benefits in distribution and synergies (A$100m a year by FY29).

The FY27 agenda, as articulated in the FY26 release, is to grow the network, drive operating leverage, enhance product differentiation, and convert the platform into sustainable profit and cash generation.

Initiatives register (last 24 months)

InitiativeDateDescription / targetsStatusSource
Merger integration and synergiesAugust 2025 (upgrade)Target raised from A$60m to A$100m a year by FY29A$13.0m delivered in 1H26; A$32.6m in FY26FY25 release; FY26 release
DC network rationalisationFY26–FY27South Guildford (WA) closed May 2026; Port Adelaide (SA) closing 1Q FY27; e-commerce DC consolidated; support centres merged at PrestonIn progressFY26 presentation
China retail exitAnnounced August 2025Progressive closure of CW bricks-and-mortar stores over two yearsIn progressFY25 release
UK market entry (Greenlight JV)MoU 4 May 2026CW brand and IP licence; 75% of initial JV stores; phase 1 up to 5 stores; first site Hoxton Street2 stores expected by December 20264 May 2026 release; FY26 release
New Zealand DCAnnounced May 202623,000 sqm Auckland DC on a 15-year leaseLive 15 September 2026Pharmacy Daily; Sigma website
UAE onlineOctober 2025E-commerce across the UAE; GCC plannedOperatingWikipedia summary
Owned and exclusive label expansionOngoing470+ new lines in FY26; sales up 15.0%OngoingFY26 release
Store refurbishmentFY2618 CW stores refurbished by franchiseesOngoingFY26 presentation
Working capital programFY27Each 1-day CCC improvement is worth about A$30m; plans in placePlannedFY26 presentation
Boots evaluationJune 2026Preliminary participation in the Boots sale processWithdrawn 15 June 2026ASX via Reuters
Sustainability reportingOctober 20262026 Sustainability Report aligned to global standards; Risk, Compliance and Sustainability Committee oversightPublishedTipRanks

Medium-term targets and guidance

TargetValueSource
SynergiesA$100m a year by FY29FY26 release
Dividend payout ratio50–70% of NPATFY26 release
Australian store rolloutConsistent with historical cadence (about 13 in 1H27)FY26 release
International store rollout19 stores in 1H27, including the UKFY26 release
Earnings guidanceNo quantitative FY27 EBIT or NPAT guidance identified. Management's outlook is positive, with continued store expansion and double-digit sales growth expected (FY26 call summary via StockAnalysis).—

Products & Services

Australia segment — retail brands (franchised)

Brand / offeringDescriptionTarget customerScale / latest dataSource
Chemist WarehouseFlagship big-box discount pharmacy: everyday low pricing, very wide range, high-volume dispensaryValue-seeking mass-market consumers561 Australian CW-branded stores at FY26 (24 added); network sales A$10.2bn, up 15.9%; LFL growth c. 13%FY26 release / presentation; Yahoo transcript summary
My ChemistSister banner to Chemist Warehouse (same ownership since 1997); same discount positioning in smaller formatsMass marketIncluded in CW-branded network figures (separate count not disclosed)Market Index; The Nightly
Amcal / Amcal+Legacy Sigma franchise banner; health-services-oriented community pharmacyCommunity / health-services customersPart of 881 Australian franchise stores (FY25); separate count not disclosed post-mergerFY25 release; ShareCafe
Discount Drug Stores (DDS)Legacy Sigma value bannerPrice-sensitive community customersCount not separately disclosed post-mergerShareCafe; Motley Fool
Guardian, PharmaSave, Chemist KingLegacy Sigma banners (historic)Community pharmacylikely consolidated or minorMotley Fool ticker profile
Optometrist WarehouseDiscount optometry format co-located with CW (since February 2023)Eyecare consumersStore count not publicly disclosedWikipedia summary
Chemist Warehouse OnlineE-commerce channel. A standalone e-commerce DC was closed and folded into the main network in FY26.Online shoppersOnline sales not separately disclosedFY26 presentation
Store refurbishment programFranchisee-funded refitsNetwork18 CW stores refurbished by franchisees in FY26 (18 also cited for 1H26)FY26 and 1H26 presentations

Australia segment — product categories and owned label

Category / offeringDescriptionLatest dataSource
Dispensary (PBS and private scripts)Prescription medicines, including GLP-1 weight-loss drugs, which management expects to drive enduring growth with flow-on benefits for adjacent categoriesGLP-1 sales cited as a structural uplift in 2H FY25; dilutive to GM%FY26 release; Macquarie Conference update
Vitamins and supplementsCore CW traffic category——
Beauty, cosmetics, fragranceHigh-margin front-of-store——
Owned and exclusive label portfolioPrivate and exclusive brands sold through the CW network; described by management as an important investment to support customer value and margin while CW remains "a house of brands"Sales approaching A$1.0bn (almost 10% of CW network sales), up 15.0%; more than 470 new lines launched in FY26 (400+ in 1H26)FY26 release; Yahoo transcript summary; Business News Australia

Individual owned-label brand names are not itemised in the sources reviewed. They are not listed here to avoid inaccuracy.

Australia segment — wholesale and services

ServiceDescriptionScaleSource
Full-line pharmaceutical wholesaleSupply of PBS medicines, OTC and front-of-store to more than 3,500 pharmacy customers579m+ units in FY26, up 6.5%ASX profile; FY26 presentation
Distribution network11 Australian DCs with more than 240,000 sqm aggregate capacity600,000+ deliveries a yearFY26 presentation via Investing.com
3PL servicesThird-party logistics for manufacturersDescribed as an increasingly important margin contributor (FY24)Legacy Sigma FY24 release
CSO distributionGovernment-funded obligation to supply PBS medicines nationallyLower CSO revenue noted in 1H25Legacy Sigma 1H25 presentation

International segment

MarketFormatScaleStatusSource
New ZealandChemist Warehouse stores; new Auckland DC (23,000 sqm, 15-year lease, live 15 September 2026)c. 70 network stores (1H26)Mature and growingNutraingredients; Pharmacy Daily; Sigma website
IrelandChemist Warehouse stores17 stores (1H26)Profitable for the first time in FY26Nutraingredients; FY26 release
UAE (Dubai)Stores plus online (launched October 2025; GCC expansion planned)2 stores (1H26)Early stageNutraingredients; Wikipedia summary
ChinaBricks-and-mortar CW storesc. 10 stores (per ASX profile)Being progressively closed over two years from August 2025FY25 release
United KingdomJV with Greenlight Healthcare (22 London pharmacies); Sigma licenses CW brand and IP and takes 75% of initial JV stores; first site Hoxton Street, east London2 stores expected by end of calendar 2026; phase 1 up to 5 storesLaunching4 May 2026 release; FY26 release; Ord Minnett
Total international—International store sales A$1.6bn, up 23.3%; LFL c. 12%; 20 stores opened in FY26; 19 planned for 1H27—FY26 presentation; Business News Australia

Financial Narrative

Structural caveat

A clean five-year series does not exist. Because of the reverse acquisition, statutory accounts from FY25 onward are those of CWG consolidating Sigma from 12 February 2025. FY25 statutory therefore contains 12 months of CWG and only about 4.5 months of legacy Sigma. Pre-FY25 CWG accounts were private (summary figures appeared in the scheme booklet). Legacy Sigma's own accounts used a January year-end.

Three series are therefore presented:

(A): The merged group on statutory, normalised and pro-forma bases.

(B): Legacy Sigma standalone (January year-ends).

(C): CWG pre-merger data points.

(A) Merged group income statement

Notes and sources:

  • FY26 revenue: A$10.8bn reported (FY26 release). A$10,835m TTM from Kalkine and StockAnalysis.

  • FY26 gross profit A$1,956.9m and 18.1% margin: FY26 presentation; Yahoo transcript summary (A$1.96bn, up 15.2%). FY25 pro-forma gross profit is derived from the 15.2% growth.

  • FY26 normalised EBITDA (derived) = net debt A$663.2m ÷ 0.57x.

  • FY26 statutory EBIT (derived) = statutory EBIT margin 9.75% × revenue.

  • FY25 statutory figures: FY25 release (27 August 2025) and FY26 results information release (statutory PBT A$743.5m; normalisations A$66.9m). Statutory NPAT A$529.9m from Pharmacy Daily, 27 August 2025.

  • FY24 normalised pro-forma EBIT of A$605.5m is from the merger prospectus, as cited in the FY26 release.

  • FY26 statutory NPAT: A$708.7m per the earnings call summary; A$709.2m per StockAnalysis. The difference likely reflects attributable vs total NPAT.

  • FY25 DPS reflects only the post-merger final dividend of 1.3c (FY25 release).

(A) Merged group margins (%)

The FY25 statutory-basis EBIT margin of 13.9% is inflated because CWG standalone (franchisor-level) margins dominate the 12-month base. Legacy Sigma's low-margin wholesale contributed only 4.5 months. The pro-forma series (9.63% to 10.06%) is the economically meaningful comparison. Source: FY26 presentation (statutory 9.75%, normalised 10.06%, pro-forma FY25 9.63%, +43bps).

(B) Legacy Sigma standalone

Notes:

  • Sources: legacy Sigma FY24 release (21 March 2024) and FY25 release (20 March 2025).

  • FY23 figures are derived from the reported FY24 changes (revenue down 9.2%; EBIT up 20.4%).

  • FY25 normalised revenue growth was 50.9%, driven by CWG supply onboarding from 1 July 2024.

  • No final dividend was paid for FY25 (January), as the merger had completed.

These figures illustrate the transformation: legacy Sigma earned roughly a 1% EBIT margin, while the merged group earns roughly 10%.

Half-year progression

1H25 pro-forma revenue is derived from the 14.9% growth rate. Sources: 1H26 release and presentation (26 February 2026); FY26 release. Implied 2H26: revenue c. A$5.3bn; normalised EBIT c. A$507m (derived). Sigma notes the first half is usually seasonally stronger.

Balance sheet

Notes:

  • Sources: FY25 release; 1H26 presentation and Appendix 4D summary (InvestSMART); FY26 release.

  • FY26 equity is derived from Kalkine's price-to-book of 5.94x and market cap of A$29.56bn at A$2.64 (7 October 2026).

  • Kalkine reports net debt of A$1,889.4m and debt/equity of 0.40. This likely includes AASB 16 lease liabilities. The discrepancy against Sigma's A$663.2m is definitional.

  • Total assets, goodwill and intangibles, short/long-term debt split and working capital for FY26 are in the FY26 Annual Report but were not extractable in this research. They are marked not publicly disclosed here. Goodwill and intangibles are known to be very large, reflecting the reverse-acquisition PPA over legacy Sigma's net assets and the CW brand.

Cash flow

Notes:

  • Sources: 1H26 presentation (OCF A$317.4m vs A$428.7m; FCF A$284.6m vs A$462.9m); FY26 presentation via StockWireX (OCF A$574.6m; FCF A$500.4m); FY26 release (capex A$56.7m).

  • Sigma defines FCF as OCF less PPE purchases, plus receipts from lease receivables.

  • Dividends paid are derived: 1H26 = FY25 final 1.3c × ~11.5bn shares; FY26 = 1.3c + 2.0c interim × ~11.5bn shares.

  • Prior-period cash flows are not like-for-like, because FY25 included only 4.5 months of legacy Sigma.

  • No buyback has been announced.

Commentary on trends, inflections and drivers

Revenue. Growth decomposes into three drivers:

  • Australian CW network momentum: LFL c. 13%, plus 24 new stores.

  • GLP-1 prescription volumes, a structural uplift that began in 2H FY25 and that Sigma expects to persist.

  • International store expansion, with revenue up 33%.

The pro-forma revenue CAGR from FY24 cannot be computed reliably because no FY24 pro-forma revenue was disclosed. On EBIT, the pro-forma CAGR from FY24 (A$605.5m) to FY26 (A$1,090.0m) is about 34% a year (derived). This compounding reflects CWG margin expansion (22.3% CWG-level margin in 1H FY25, versus 18.3% a year earlier), internalisation of wholesale margin, and synergies.

Margins. Pro-forma gross margin held flat at 18.1% despite mix dilution from GLP-1s, which are high-value, low-margin scripts. Operating leverage is the main EBIT margin driver. Normalised operating expenses rose 9.9% against revenue growth of 15.5%: A$860.4m in FY26 versus A$782.9m pro-forma FY25 (FY26 presentation). Synergies of A$32.6m were delivered in FY26 (A$13.0m in 1H26), against a target of A$100m a year by FY29. The FY29 target was raised from A$60m in August 2025.

Earnings quality. The statutory-to-normalised gap narrowed sharply. FY25 normalisations totalled A$66.9m at the PBT level; FY26 statutory NPAT of A$708.7m was only about 3% below normalised NPAT of A$732.3m. This is consistent with fading one-off merger costs. Ongoing PPA amortisation will, however, keep statutory below normalised.

Cash. FY26 FCF of A$500.4m equalled about 68% of normalised NPAT. Management highlighted working capital, specifically the 54-day CCC, as an explicit cash lever. The 1H26 OCF decline versus pcp reflected the larger merged working capital base and normalisation of CWG's pre-merger working capital.

Balance sheet. Leverage is conservative at 0.57x net debt to EBITDA and falling. This gives capacity for international expansion, as shown by the Boots evaluation and withdrawal, or for higher distributions. No buyback has been announced.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsKey products / services

Australia

Wholesale and distribution to the Chemist Warehouse, My Chemist, Amcal and DDS networks and to independents; franchise income; owned and exclusive label; 3PL; CSO; Australian online

PBS and private prescriptions, OTC, vitamins, beauty, fragrance, personal care; logistics services

International

Chemist Warehouse stores and online in New Zealand, Ireland, UAE, China (closing) and UK (from 2026)

Retail pharmacy and front-of-store; NZ DC from September 2026

Revenue by Segment and Segment Margins & Growth (%)

MetricFY25FY26

Australia revenue (AUD Mn, derived)

9,06310,414

International revenue (AUD Mn)

317421

Group revenue (AUD Mn)

9,38010,835

Australia normalised EBIT (AUD Mn)

874.31,034.2

International normalised EBIT (AUD Mn, FY25 derived)

29.255.8

Group normalised EBIT (AUD Mn)

903.41,090.0

Australia EBIT margin (%)

9.659.93

International EBIT margin (%, derived)

9.213.2

Australia gross margin (%)

—17.6

International gross margin (%)

27.630.6

Segment Overview — Australia

SegmentRevenue growthEBIT growth% of group revenue% of group EBIT

Australia

+14.9%+18.3%96.1%94.9%

International

+33.0%+91.3%3.9%5.1%

Income Statement and Per-Share Data

MetricFY24FY25FY26

Revenue – statutory (AUD Mn)

—6,008.510,835

Revenue – pro-forma comparable (AUD Mn, FY25 derived)

—9,38010,835

Gross profit (AUD Mn, FY25 pro-forma derived)

—1,6991,957

Normalised EBITDA (AUD Mn; FY25 statutory basis; FY26 derived)

—884.11,163

Normalised EBIT – statutory basis (AUD Mn)

—834.51,090.0

Normalised EBIT – pro-forma basis (AUD Mn)

605.5903.41,090.0

Statutory EBIT (AUD Mn, FY26 derived)

——1,056

Statutory profit before tax (AUD Mn)

—743.5—

Statutory NPAT (AUD Mn)

—529.9708.7

Normalised NPAT (AUD Mn, FY25 pro-forma derived)

—598.8732.3

Normalised EPS (A cents, FY25 derived)

—5.276.4

Statutory EPS basic (A cents)

——6.2

Dividends per share (A cents)

—1.34.0

Margin Analysis (%)

MetricFY25FY26

Gross margin – pro-forma (%)

18.118.1

Normalised EBIT margin – pro-forma (%)

9.6310.06

Statutory EBIT margin (%)

—9.75

Normalised EBIT margin – statutory basis (%, derived)

13.910.06

Normalised NPAT margin – pro-forma (%, derived)

6.46.8

Statutory net margin (%, derived)

8.86.5

Income Statement and Margin Analysis (%)

MetricFY23FY24FY25

Net revenue (AUD Mn, FY23 derived)

3,6593,322.14,841.2

Statutory EBIT (AUD Mn, FY23 derived)

19.323.221.7

Normalised EBIT (AUD Mn)

—31.468.0

Normalised NPAT (AUD Mn)

—12.7—

Normalised EBIT margin (%)

—0.91.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Valuation Snapshot

MetricValuePeriodSource

CWG statutory revenue (AUD Mn)

3,090 (prior year 2,990)

FY23 (12 months to 30 June 2023)

CWG accounts, as reported by Market Matters (secondary)

CW retail network sales (AUD Mn)

5,154.0 (prior 4,559.4), up 13.0%

1H FY25 (6 months to 31 December 2024)

CWG trading update, 28 January 2025

CWG EBIT (AUD Mn)

437.9 (prior 324.3), up 35.0%

1H FY25

CWG trading update

CWG EBIT margin (%)

22.3 (prior 18.3)

1H FY25

CWG trading update

LFL network sales growth (%)

10.3 (prior 8.9)

1H FY25

CWG trading update

Combined Sigma + CWG EBIT (AUD Mn)

c. 500

FY23

Sigma commentary, as reported by Market Matters (secondary)

Income Statement and Margin Analysis (%) (FY26)

Metric1H25 pro-forma1H26FY26

Revenue (AUD Mn)

4,7875,50010,835

Normalised EBIT (AUD Mn)

491.0582.91,090.0

Normalised NPAT (AUD Mn)

328.9392.0732.3

Gross margin (%)

—18.318.1

Normalised EPS (A cents)

—3.46.4

DPS (A cents)

—2.04.0

Balance Sheet and Financial Ratios (x)

MetricFY251H26FY26

Cash and equivalents (AUD Mn)

138.8160.5—

Net debt (AUD Mn, excl. leases)

752.2635.1663.2

Net debt / normalised EBITDA (x)

0.850.600.57

Total equity (AUD Mn; FY26 derived)

4,6604,8904,980

Cash Flow

Metric1H25FY251H26FY26

Operating cash flow (AUD Mn)

428.7—317.4574.6

Capital expenditure (AUD Mn)

———56.7

Free cash flow (AUD Mn)

462.9—284.6500.4

Dividends paid (AUD Mn, derived)

——150380

Share buybacks (AUD Mn)

0000

Margin Analysis (%) and Financial Ratios (x)

RatioFY26 valueBasis / source

ROE (%)

14.7

Kalkine TTM. Derived check: statutory NPAT A$708.7m / average equity ~A$4.82bn = 14.7%.

ROCE (%)

13.7

Kalkine TTM

Debt / equity (x)

0.40

Kalkine (likely includes leases)

Net debt / normalised EBITDA (x)

0.57

FY26 release

Cash conversion cycle (days)

54.0 (described as having risen); each 1-day improvement is estimated to release c. A$30m of cash

FY26 presentation via StockWireX

Cash conversion (FCF / normalised NPAT, %)

68

Derived: 500.4 / 732.3

Dividend payout ratio (%)

63.0 (target range 50–70% of NPAT)

FY26 presentation / release

Capex / revenue (%)

0.5

Derived

Revenue by Region and Revenue by Region (%)

RegionFY25FY26

Australia revenue (AUD Mn)

9,06310,414

International revenue (AUD Mn)

317421

International share of group revenue (%)

3.43.9

Revenue by Region

NetworkFY25FY26

Australian CW-branded network sales (AUD Mn)

8,80010,200

International store sales (AUD Mn)

1,3001,600

Total CW retail network sales (AUD Mn)

10,30011,800

Country Overview

CountryStores (latest)Trend / commentarySource

Australia (CW-branded)

561 (FY26); 550 (1H26); 537 implied at FY25

+24 in FY26; 13 planned for 1H27

FY26 release; 1H26 release

Australia (all franchise banners)

881 (FY25)

Includes Amcal and DDS

FY25 release

New Zealand

c. 70 (1H26)

Growth market; new DC September 2026

Nutraingredients

Ireland

17 (1H26)

First profitable year in FY26

Nutraingredients; FY26 release

UAE

2 stores plus online

Online launched October 2025

Nutraingredients; Wikipedia summary

China

c. 10 (pre-closure)

Closing progressively over two years from August 2025

ASX profile; FY25 release

UK

0 (2 expected by December 2026)

Greenlight JV

FY26 release

Total international

97 (1H26); c. 98 cited post-FY26

20 opened in FY26, partly offset by China closures

1H26 release; Business News Australia

Valuation Snapshot — Last close

MetricValueSource / date

Last close

A$2.80 (15 October 2026); A$2.81 (14 October 2026)

HotCopper; Listcorp

52-week range

A$2.47 – A$3.20

ad-hoc-news; StockAnalysis (October 2026)

FY26 result-day close

A$2.62 (down 7.75%), 27 August 2026

Kalkine

Post-Boots-withdrawal close

A$2.80 (up 6.1%), 15 June 2026

MoneyAM

1-year performance

About –7% over 12 months to late August 2026 (underperformed the ASX 200)

Motley Fool, 27 August 2026

3-year performance

Strongly positive. Shares had risen about 256% from 11 December 2023 (merger announcement) to January 2025.

Motley Fool, January 2025

5-year performance

Strongly positive, driven by the merger re-rating.

—

Beta

0.32

StockAnalysis

Share Price

MetricJun-2025Feb-2026Jun-2026Aug-2026Oct-2026

SIG share price (AUD)

2.992.942.802.622.80

Valuation Multiples

MultipleSigmaSource

Trailing P/E (statutory)

41.7–45.6x

StockAnalysis; ad-hoc-news

Forward P/E

c. 34x

StockAnalysis; Kalkine

EV/EBITDA (trailing)

27.8x

Kalkine

EV/Sales

2.91x

Kalkine

Price/Sales

2.73x

Kalkine

Price/Book

5.94x

Kalkine

Dividend yield

c. 1.5% fully franked

StockAnalysis; Listcorp

Analyst Ratings & Targets

BrokerRatingTarget (AUD)DateSource

Consensus (16 analysts)

Buy

3.20 average

October 2026

StockAnalysis

Morgan Stanley

Buy

3.30

21 September 2026 (reiterated 13 October 2026)

ad-hoc-news / Markets Insider

Macquarie

Buy

3.20

5 October 2026

ad-hoc-news

Ord Minnett

Buy

3.40

15 May 2026

Ord Minnett

UBS

(Buy implied)

3.40

December 2025

Motley Fool

Jarden

Overweight

3.30—

FNArena

Goldman Sachs

Buy

——

StockAnalysis news list

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY25FY26

Interim DPS (A cents)

02.0

Final DPS (A cents)

1.32.0

Total DPS (A cents)

1.34.0

Payout ratio (%)

—63.0

Analyst Conclusions

Management guidance

Sigma did not issue quantitative FY27 earnings guidance. It did set operational markers:

  • 13 Australian CW stores in 1H27.

  • 19 international stores in 1H27, including 2 UK stores by December 2026.

  • Synergies on track for A$100m a year by FY29.

  • Port Adelaide DC closure in 1Q FY27.

  • Working capital improvement initiatives.

Commentary on the FY26 call pointed to continued double-digit sales growth (FY26 release; StockAnalysis call summary).

Consensus expectations

The average target price of A$3.20 implies about 14% upside from A$2.80. The forward P/E of about 34x against a trailing P/E of about 42–46x implies consensus expects roughly 20–25% EPS growth into FY27 (derived from the multiples).

Bull case

  1. Compounding operating leverage. EBIT growth has outpaced revenue growth every period since the merger (FY26: +20.6% vs +15.5%). Another roughly A$67m of synergies is still to come, and DC consolidation continues.

  2. Structural demand tailwinds. GLP-1 adoption, LFL growth of 13–15%, and a steady rollout of 24–26 stores a year support high-single to low-double-digit network growth for years.

  3. International optionality at low cost. Ireland's breakeven, the New Zealand DC and the capital-light UK licence model could make International a material earnings contributor, with EBIT already up 91% in FY26.

Bear case

  1. Valuation leaves no margin for error. At about 28x EV/EBITDA, the stock fell 6–8% on both the 1H26 and FY26 results despite double-digit growth. Expectations are very high.

  2. Founder overhang. About 43% of capital became tradable on 27 August 2026. The 2025 sell-downs exceeded A$1.3bn, and further block sales could cap the share price.

  3. Margin mix and policy risk. GLP-1s dilute gross margin percentage, the CCC is rising, and PBS or pharmacy regulation could change the economics of both franchise and wholesale.

Key catalysts and monitorables (next 12 months)

CatalystExpected timing
2026 AGM (remuneration vote, LTI approvals, any trading update)21 October 2026
UK first store openings (Hoxton Street and a second site)By December 2026
Port Adelaide DC closure1Q FY27 (July–September 2026); confirmation due
Founder shareholding notices and any block tradesOngoing
1H27 results (synergy run-rate, LFL against GLP-1 comps, CCC progress)Late February 2027
International store rollout (19 in 1H27) and New Zealand DC ramp-upThrough FY27
PBS and pharmacy policy developmentsOngoing
Capital management (payout within 50–70%; any buyback)1H27 / FY27 results

Analyst verdict

Sigma Healthcare has, in less than two years, been transformed from a marginal, low-return wholesaler into one of the highest-quality retail franchisors on the ASX. FY26, the first full merged year, delivered on the merger thesis. Revenue reached A$10.8bn (up 15.5%), normalised EBIT A$1.09bn (up 20.6%) and normalised NPAT A$732.3m (up 22.3%). Leverage fell to 0.57x, and free cash flow of A$500m was generated on capex of under A$60m. The Chemist Warehouse format continues to take share, with LFL growth of about 13% on a A$10bn base. Integration is on schedule, and management showed welcome capital discipline by walking away from Boots.

The debate is therefore about price and supply, not quality. A trailing EV/EBITDA of about 28x and a P/E above 40x already discount several years of double-digit compounding. The market's reaction to two successive strong results (down 6–8% on each) shows how little execution premium remains. The release of more than five billion founder shares from escrow creates a persistent overhang, partly offset by Mario Verrocchi's September 2026 on-market purchase. Governance is adequate but not best-in-class, given founder control and a board that, on the composition verified here, lacks an independent majority. The thin 18% gross margin means mix shifts toward high-value scripts must be offset by private label and supplier support.

On balance, Sigma is a structurally advantaged compounder, best owned by long-horizon investors who accept a full multiple. The medium-term value drivers are synergy delivery to A$100m, working capital release of about A$30m per day of CCC, and proof that the UK licence model travels. Near-term share price direction will depend more on founder selling behaviour and the trajectory of GLP-1 comparatives than on fundamentals. Analyst stance: constructive on fundamentals, neutral-to-positive on valuation, with consensus targets of about A$3.20–3.40 implying low-to-mid-teens upside.


Source note: Figures are taken from Sigma Healthcare ASX releases and presentations (FY24–FY26), the Chemist Warehouse Group trading update (January 2025) and the market and news sources named in each table. Figures marked "derived" are arithmetic computations by the analyst from disclosed data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleSinceBackgroundIndependenceSource

Michael Sammells

Non-Executive Chair

Sigma director pre-merger; Chair post-merger

Former Sigma board member; leads merged board

Independent

Forbes (merger documents); escrow release

Vikesh Ramsunder

CEO & Managing Director

CEO since c. 2022 (Simply Wall St); MD of merged group since February 2025

B.Com, MBL; led the Sigma turnaround and the CWG supply win and merger

Executive

Simply Wall St; Forbes

Mario Verrocchi

Executive Director; CEO – Retail

February 2025

Joined the Gance group in 1982; co-founded MyChemist (1997) and Chemist Warehouse (2000); member of the Risk, Compliance and Sustainability Committee

Executive (founder; c. 22% holder)

Market Index director profile

Jack Gance

Non-Executive Director

February 2025

Co-founder; opened the first pharmacy in 1972

Non-independent (c. 12–14% holder)

Motley Fool director table; AFR

Damien Gance

Non-Executive Director (Executive Director until 2025)

February 2025

Pharmacist; joined MyChemist in 1998; first CW franchisee; former Chief Commercial Officer of CWG; stepped down from executive duties in 2025

Non-independent

Executive changes release (27 August 2025); Motley Fool

Danielle Di Pilla

Executive Director

February 2025

CWG Chief People Officer; cousin of Mario Verrocchi

Executive

Forbes

Annette Carey

Non-Executive Director

Pre-merger Sigma director

Prior Sigma board

Independent

Forbes

Neville Mitchell

Non-Executive Director

Pre-merger Sigma director

Chair of Fisher & Paykel Healthcare; NED of Sonic Healthcare since September 2017; international healthcare and finance experience

Independent

Motley Fool director profiles

Chris Roberts

Non-Executive Director

Pre-merger Sigma director

Directorships linked to HMC Capital-managed vehicles, Clarity Pharmaceuticals and the Cochlear Foundation (per profile excerpt)

Independent

Forbes; Motley Fool profile excerpt

Executive Leadership Team

NameTitleTenure / notesSource

Vikesh Ramsunder

CEO & Managing Director

See above

—

Mario Verrocchi

CEO – Retail

Since merger

Notice of AGM 2026

Mario Tascone

Deputy CEO – Retail

Appointed August 2025 (previously CWG COO); responsible for day-to-day retail operations

Executive changes release; Pharmacy Daily

Richard Murray

Chief Financial Officer

Appointed after Mark Davis's departure; presented 1H26 results (February 2026)

1H26 presentation; TipRanks headline

Mark Davis

Former Group CFO

Gave notice in August 2025; transitioned pending successor

Executive changes release

Mark Conway

Promoted August 2025

—

Executive changes release

Executive Leadership Team by Executive

ExecutiveItemAmountPeriod / source

Vikesh Ramsunder

Total reported remuneration

A$5.71m

FY25 (Simply Wall St).

Vikesh Ramsunder

Shares issued under incentive plans

813,449 shares (A$2.35m value)

9 January 2026 (Motley Fool director dealings)

Vikesh Ramsunder

Proposed 2026 LTI

1,084,167 rights

Notice of AGM 2026

Mario Verrocchi

Total reported remuneration

A$396.9k

FY25 (Simply Wall St)

Mario Verrocchi

Shares issued

314,021 shares (A$0.91m)

9 January 2026

Mario Verrocchi

Proposed 2026 LTI

349,060 rights

Notice of AGM 2026

Danielle Di Pilla

Shares issued

141,591 shares (A$0.41m)

9 January 2026

Major Shareholders

HolderShares% of issued capitalSource / date

Mario Verrocchi and associates

2,555,284,92022.13%

Substantial holder data (InvestSMART); escrow release, 9 July 2026

Jack Gance and associates

1,579,050,058 (substantial notice) / 1,423,948,843 (escrow notice)

13.67% / c. 12.3%

InvestSMART; escrow release

Sam Gance and associates

1,446,864,015 (substantial notice) / 1,326,864,015 (escrow notice)

12.53% / c. 11.5%

InvestSMART; escrow release

Damien Gance

Not disclosed precisely (top-5 holder per Simply Wall St)

—

Simply Wall St

Challenger Limited

Bought 23.4m shares in February 2025; current stake not disclosed

<5%

Simply Wall St

Institutions (aggregate)

—

c. 6–15% (estimates vary by data vendor)

Simply Wall St

General public (retail, including former CWG franchisee holders)

—

c. 31–35%

Simply Wall St

Competitive Landscape

Key Competitors

CompetitorSegment(s)Key brands / descriptionLatest scaleSource

EBOS Group (ASX/NZX: EBO)

Wholesale; retail pharmacy banners

Symbion (wholesale), TerryWhite Chemmart, Cincotta Chemist; also animal care

FY26 revenue c. 13.5bn (up 9.9%); underlying profit 614m; NPAT 225.2m; community pharmacy revenue 7.1bn; TWC sales 2.9bn. EBOS reports in NZ$; Australian media reported these as "$".

Pharmacy Daily; Motley Fool, 19 August 2026

Wesfarmers Health (division of ASX: WES)

Wholesale (former API); retail franchise

Priceline Pharmacy, Soul Pattinson Chemist, Clear Skincare, MediAesthetics, InstantScripts

FY26 revenue A$6,474m (up 9.1%); earnings A$76m (up 18.8%); Priceline network sales up 12.7%; 23 new stores

Wesfarmers FY26 results; Business News Australia

Woolworths Group

Front-of-store OTC, vitamins, beauty

Supermarket health and beauty aisles

Category-level data not disclosed

—

Coles Group

Front-of-store OTC, vitamins, beauty

Supermarket health and beauty

——

Blooms The Chemist

Retail pharmacy franchise

Community pharmacy banner

Private; not disclosed

—

National Pharmacies

Retail pharmacy (member-owned, SA/VIC)

Mutual-owned pharmacy chain

——

Good Price Pharmacy Warehouse

Discount pharmacy retail

Direct discount-format competitor

Private; not disclosed

—

Pharmacy 4 Less / Direct Chemist Outlet

Discount pharmacy

Discount formats

Private; not disclosed

—

Amazon Australia; online pharmacies (e.g., Your Discount Chemist)

E-commerce health and beauty

Online marketplaces, including Temu-listed pharmacy sellers

—

Pharmacy Daily

Mecca / Sephora

Beauty and cosmetics

Prestige beauty

——

Green Cross Health (NZ)

NZ retail pharmacy

Unichem, Life Pharmacy

——

Bargain Chemist (NZ)

NZ discount pharmacy

Direct NZ discount competitor

——

Boots, Superdrug, Tesco, Sainsbury's (UK)

UK pharmacy and health & beauty

Incumbents a CW UK entry must compete with

Boots has about 1,800 stores

City AM; Nutraingredients

Boots Ireland, Hickey's, McCabes (Ireland)

Irish pharmacy retail

Incumbents

——

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricSigma HealthcareEBOS GroupWesfarmers Health

Revenue (local m)

10,83513,4876,474

Revenue growth (%)

15.59.99.1

EBIT / earnings (local m)

1,090—76

EBIT margin (%)

10.1—1.2

Net profit (local m)

709225.2—

Company Snapshot

$3,123.4M

Revenue

Preston, Australia

Headquarters

SWOT Analysis

Strengths

  • Dominant scale. Australian CW network sales were A$10.2bn in FY26 (up 15.9%) across 561 stores, versus TerryWhite Chemmart sales of A$2.9bn (FY26 releases of Sigma and EBOS).
  • Operating leverage. Normalised EBIT rose 20.6% on revenue growth of 15.5%; the pro-forma EBIT margin expanded 43bps to 10.06% (FY26 presentation).
  • Strong LFL momentum. About 13% Australian LFL in FY26, 15.0% in 1H26 and 11.3% in FY25 (FY26 call summary; 1H26 release; FY25 release).
  • Conservative balance sheet. Net debt of A$663.2m is 0.57x normalised EBITDA, down from 0.85x (FY26 release).
  • Cash generation. FY26 FCF of A$500.4m on capex of only A$56.7m (FY26 presentation; release).
  • Supplier standing. Ranked No.1 wholesaler in the Advantage Group survey, 4Q FY26 (FY26 presentation).
  • Private label scale. Approaching A$1.0bn of sales (up 15.0%), with 470+ new lines (FY26 release).

Weaknesses

  • Thin gross margin. The group gross margin is 18.1% and the Australian segment 17.6%. GLP-1s are explicitly dilutive (FY26 release).
  • Governance concentration. Founders hold about 48% of shares.
  • Rising cash conversion cycle. The CCC rose to 54.0 days; working capital absorbs cash (FY26 presentation).
  • Reporting complexity. Reverse-acquisition accounting and multiple bases (statutory, normalised, pro-forma) obscure trends. Pro-forma revenue was itself reclassified (19 February 2026 release).
  • Small international base. International is 3.9% of revenue, and China failed and is being exited (FY25 release).
  • Statutory/normalised gap. Ongoing PPA amortisation; A$66.9m of FY25 normalisations at PBT (FY26 results information release).

Opportunities

  • Synergies. A further c. A$67m of annual synergies remains to reach the A$100m FY29 target (A$32.6m delivered in FY26).
  • UK entry. The Greenlight JV gives low-capital access to a market where Boots has about 1,800 stores. Phase 1 covers 5 stores, with optionality beyond (4 May 2026 release; City AM).
  • Working capital release. Each 1-day CCC improvement is worth about A$30m (FY26 presentation).
  • New Zealand DC. Supply chain control in the largest international market (live September 2026).
  • GLP-1 adjacency. Management expects flow-on benefits to adjacent categories such as nutrition and fitness (FY26 release).
  • DC consolidation. WA consolidated; Port Adelaide closing in 1Q FY27 (FY26 presentation).
  • Middle East online. UAE online launched October 2025, with GCC expansion planned.

Threats

  • Founder share overhang. 5.02bn shares (about 43% of capital) were released from escrow on 27 August 2026 (9 July 2026 release). The family sold more than A$1.3bn of shares in 2025.
  • Regulatory change. The PBS, Community Pharmacy Agreement and pharmacy location and ownership rules are all policy-dependent.
  • Competitor investment. Wesfarmers Health is opening new Adelaide and Perth fulfilment centres in FY27 and expanding Priceline (23 new stores in FY26) (Wesfarmers FY26 results).
  • Online disruption. Online pharmacy marketplaces, including Temu-listed sellers, are expanding reach (Pharmacy Daily).
  • Valuation sensitivity. The trailing P/E of about 42–46x leaves little room for disappointment. Shares fell 7.75% on the FY26 result day (Kalkine; ad-hoc-news).
  • M&A discipline risk. Large-cap overseas deal appetite was signalled by the Boots evaluation, even though Sigma withdrew (June 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 April 2025Damien Gance sells 140m shares (c. A$418m) Simply Wall St / Motley FoolFounder-family sell-down post-merger
9 May 2025Damien Gance sells a further 126.5m shares (c. A$382m) Motley FoolContinued supply overhang
29 May 2025Executive Director Danielle Di Pilla sells 29.8m shares (A$94.5m) Simply Wall StInsider selling
27 August 2025FY25 results: revenue A$6.0bn statutory; normalised EBIT up 41.4%; pro-forma EBIT A$903.4m; statutory NPAT A$529.9m; synergy target raised to A$100m; final dividend 1.3c FY25 release; Pharmacy DailyFirst merged result; synergy upgrade
27 August 2025China store closure decision announced FY25 releasePortfolio pruning
27 August 2025Executive changes: CFO Mark Davis to step down; Damien Gance to NED; Mario Tascone becomes Deputy CEO Retail; Mark Conway promoted ASX executive changes releaseLeadership reshaping
28 August 2025Jack Gance sells 155.1m shares (A$480.8m) Motley FoolFounder sell-down
September 20252025 Annual Report and 2025 AGM notice released TipRanksGovernance
Late 2025Richard Murray appointed CFO TipRanks headline; 1H26 presentationCFO succession completed
1Q FY26GLP-1s lift CW sales growth in 1Q FY26 (CEO commentary) AJPDemand driver
October 2025CW UAE online launch; 16th Irish store Wikipedia summary; RTÉInternational progress
December 2025Shares slide towards the 2025 low of A$2.74; UBS target A$3.40 Motley Fool, 9 December 2025Sentiment weakness
9 January 2026Incentive shares issued to Ramsunder, Verrocchi and Di Pilla Motley FoolRemuneration
19 February 20261H26 results information release, including restated comparatives and reverse-acquisition presentation ASXReporting transparency
26 February 20261H26 results: revenue A$5.5bn (up 14.9%); normalised EBIT A$582.9m (up 18.7%); normalised NPAT A$392.0m; interim dividend 2.0c; net debt A$635.1m. Shares fall c. 6% intraday. 1H26 release; InvestSMARTSolid result; market expected more
4 March 2026Ex-date for the 2.0c interim dividend (paid 20 March 2026) ListcorpCapital return
4 May 2026Greenlight UK MoU; Auckland DC lease; trading update shows FY26 YTD Australian CW sales up 16.7% and international up 24.7% ASX; Ord MinnettInternational expansion
5–6 May 2026Macquarie Australia Conference presentation Sigma websiteInvestor engagement
15 May 2026Ord Minnett raises target to A$3.40 ("London Calling")Broker support
May 2026South Guildford DC closed FY26 presentationCost efficiency
~10 June 2026Sigma confirms early-stage talks to acquire Boots Reuters / Bloomberg via ForbesMajor M&A risk event
15 June 2026Withdraws from Boots; shares close up 6.1% at A$2.80 MoneyAM; City AMCapital discipline welcomed
9 July 2026Escrow release notice (5.02bn shares from 27 August 2026); founders affirm commitment ASXOverhang risk
July 2026Segment reporting changed to Australia and International; FY25 segment comparatives released FY26 results information releaseReporting change
25–26 August 20262026 AGM date set (21 October); director nominations close 1 September Globe and Mail / TipRanksGovernance
27 August 2026FY26 results: revenue A$10.8bn; normalised EBIT A$1,090.0m; normalised NPAT A$732.3m; final dividend 2.0c; net debt A$663m. Shares close down 7.75% at A$2.62. FY26 release; KalkineFirst full merged year
27 August 2026Founder escrow released at close ASXSupply overhang crystallises
3 September 2026Ex-date for the final dividend (paid 22 September) TipRanksCapital return
15 September 2026New Zealand DC goes live Sigma websiteInternational infrastructure
16 September 20262026 Appendix 4E and Annual Report lodged ListcorpFiling
18 September 2026Mario Verrocchi buys 2m shares on-market (A$5.1m) Market IndexInsider buying signal
18 September 2026Notice of AGM / proxy form issued ListcorpGovernance
21 September 2026Morgan Stanley Buy, target A$3.30 (reiterated 13 October) ad-hoc-news / Markets InsiderBroker support
28 September 2026Notice of ceasing to be a substantial holder (holder not identified in sources) ListcorpRegister change
5 October 2026Macquarie Buy, target A$3.20 ad-hoc-newsBroker support
9 October 2026Sustainability Report 2026 released TipRanksESG disclosure
14 October 2026Shares rise 3.3% to A$2.81 ListcorpRecovery from post-result low

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue – statutory rose from AUD 6,008.5 Mn in FY2025 to AUD 10,835 Mn in FY2026.
Sigma Healthcare Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2025FY2026
Revenue – statutory6,008.510,835
Revenue – pro-forma comparable9,38010,835
Gross profit1,6991,957

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.